Royalty Report: Medical, Device, Delivery – Collection: 372446


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Medical
  • Device
  • Delivery
  • Surgical
  • Drugs
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 372446

License Grant
Having been made aware of the rights of Licensor, an individual of France with regard to the invention, the Licensee of the Netherlands now intends to recognize these rights in order to guarantee untroubled use of the patent.

The Licensee acknowledges Licensors role as the co-inventor of the invention and therefore that she had a right to be the co-owner of the patent and its international extensions which protect the device for the intraocular transfer of active substances by iontophoresis.

By this agreement, Licensor of France renounces her right to take action against the Licensee of the Netherlands for recovery of the registered patents.

License Property
Licensor played a decisive role in development work on the applicator, a major part of the device.

Certain patents with respect to and which are used in Licensee's EGP-437 Combination Product.

US patent application N°09/225,206 (now granted, N° 6,154,671)

Field of Use
The licensed device is for the intraocular transfer of active substances by iontophoresis.
Iontophoresis is a process of transdermal drug delivery by use of a voltage gradient on the skin.

EGP-437 in clinical trials, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, that is delivered into the ocular tissues though our proprietary innovative drug delivery system, the EyeGate® II Delivery System.

The EyeGate® II Delivery System and EGP-437, are designed to address two major issues in ophthalmic medicine lack of patient compliance and safety. The EyeGate® II Delivery System features a compact, elegant, and easy-to-use device that we believe has the potential to deliver drugs non-invasively and quickly into the ocular tissues through the use of iontophoresis, which can accelerate the onset of action, dramatically reduce treatment frequency versus eye drops and sustain therapeutic effect. Iontophoresis employs the use of a low electrical current that promotes the migration of a charged drug substance across biological membranes.

IPSCIO Record ID: 260371

License Grant
The University grants to the Licensee of France an exclusive license in the Territory for the Field of Use, with the right to sub license, under the Scientific Results and Know-How,  to research, develop, make, have made, use and sell Products and  to practice the Scientific Results, the Know-How and all of the inventions disclosed in the Report of Invention Disclosure.

Licensor grants the authority to make any application for patents, including patent applications related to Scientific Results, in the name of Licensee; all expenses of obtaining and maintaining said patents shall be paid by Licensee.

License Property
The Licensor has rights to the technology and product identified as a non-invasive device for transfer of pharmaceutical agents drugs, biomolecules and dyes in the eyes, orbital tissues, and tissues surrounding the eye,  the Scientific Results of the Original License Agreement and the Know-How as defined in the Original License Agreement.
Field of Use
The Field of Use shall mean medical treatment for eyes by iontophoresis.

IPSCIO Record ID: 2759

License Grant
The Licensee, a spin-off of the Licensor purchased assets of iontophoresis drug delivery products and related research and development program, as well as related patents, patent applications and other intellectual property.
License Property
Iontophoresis is an active transdermal drug delivery technology.

The Licensee has developed and produced the first FDA – approved electronically controlled transdermal drug delivery system that transports drugs through the skin comfortably, without needles.  Our active transdermal drug delivery technology is based on a process known as electrotransport, or more specifically iontophoresis, a process that transports drugs, including peptides, through the skin by applying a low-level electrical current. Our active patch patented technology works by applying a charge to the drug-holding reservoir of the patch. This process differs significantly from passive transdermal drug delivery which relies on the slow, steady diffusion of drugs through the skin. A significantly greater number of drugs can be delivered through active transdermal delivery than is possible with passive transdermal delivery. Based on our analysis thus far, we estimate that there are currently over 220 FDA-approved drugs that may be delivered through our active transdermal delivery platform.

Field of Use
The Licensee is required to pay the Licensor a royalty in respect of sales of each iontophoresis product stemming from intellectual property received from the Licensor.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.